dr ashish joshi | indirect comparison of mobocertinib trial data vs real world data in patients
Published 1 year ago • 163 plays • Length 10:12Download video MP4
Download video MP3
Similar videos
-
12:34
dr ashish joshi | interpretation of pd1 msi tmb in nsclc
-
8:12
dr ashish joshi | 1462p - clinical outcome of patients with non-clear metastatic rcc treated
-
20:12
oncopulmo pearl - dr ashish joshi - immunotherapy for lung cancer whats new
-
11:18
dr ashish joshi | current treatment landscape in first line urothelial cancer
-
42:53
biomarkers in cancer immunotherapy: how much do they matter?
-
0:46
how is usc different in lung cancer screening? lung cancer answers
-
2:04
ask the expert: is there a link between air quality and the prevalence of asthma
-
1:13:19
state-of-the-art in combination immuno/radiotherapy for non-small cell lung cancer
-
0:37
how do side effects from immunotherapy differ from side effects from chemotherapy in lung cancer?
-
0:33
3 types of hysterectomy #shorts #shortsfeed
-
59:36
ilcn multidisciplinary forum: understanding treatment options and resistance in egfr-positive nsclc
-
23:39
breast cancer- what should women know!
-
5:05
measuring quality of lung surgery-mayo clinic
-
2:49
what is multi-focal lung cancer?
-
2:28
which biomarkers exist for non-small cell lung cancer (nsclc)?
-
5:57
prognostic value of circulating tumour-cell count in metastatic breast cancer patients
-
0:58
kidney cancer scan types | national kidney foundation
-
1:16
expert opinion | role of liquid biopsy in lung cancer | prof. nir peled
-
5:37
lung cancer | q&a